Want to see LTRN full AI Analyst Report?
LTRN Stock Chart & Stats
$2.75
$0.04(1.45%)
At close: 4:00 PM EDT
$2.75
$0.04(1.45%)
Day’s Range― - ―
52-Week Range$1.11 - $4.98
Previous CloseN/A
Volume2.60K
Average Volume (3M)159.65K
Market Cap
$36.49M
Enterprise Value$9.15
Total Cash (Recent Filing)$6.32M
Total Debt (Recent Filing)$59.08K
Price to Earnings (P/E)―
Beta2.35
Next Earnings
Aug 14, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.45
Shares Outstanding12,758,872
10 Day Avg. Volume114,283
30 Day Avg. Volume159,645
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)5.05
Price to Sales (P/S)0.00
P/FCF Ratio-2.11
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$25.00Price Target Upside809.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.51
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
AI Platform Spinoff And LicensingSeparating the RADR/withZeta.ai capability into Open‑Medicine AI (OMAI) creates a standalone commercial vehicle and licensing path. That structure provides durable monetization optionality, expands addressable markets beyond Lantern’s pipeline, and preserves strategic ties to Lantern’s clinical programs.
Low LeverageVery low reported debt reduces fixed financial obligations, giving management flexibility to prioritize R&D and clinical programs. For development-stage biotech, low leverage lowers default risk, simplifies future financings, and preserves strategic optionality during long clinical timelines.
Multi-asset Clinical PipelineHaving multiple clinical-stage candidates (including mid-stage LP-300 and LP-184 activity) spreads binary clinical risk across assets. Durable value creation can come from staged clinical readouts, regulatory progress or partnerships, making the company less dependent on any single trial outcome.
Bears Say
Chronic Cash BurnPersistent negative operating and free cash flow means the business cannot self-fund development. Losses translate into real cash usage, which forces repeated capital raises or partner deals, increasing dilution risk and constraining long-term planning if clinical milestones slip or market conditions tighten.
No Commercial RevenueAbsence of product revenue leaves the company fully dependent on financing, collaborations or asset exits for sustainability. Persistent multi-year losses mean intrinsic value hinges on successful clinical development or licensing, making cash runway and trial outcomes the central long-term risks.
Financing Overhang And Balance Sheet VolatilityRecent financings and issued warrants create a structural overhang and potential future dilution. Coupled with reported sharp inconsistencies in equity across periods, this indicates balance-sheet scale and capitalization have fluctuated, complicating long-term equity holders’ dilution exposure and planning.
Lantern Pharma News
LTRN FAQ
What was Lantern Pharma, Inc.’s price range in the past 12 months?
Lantern Pharma, Inc. lowest stock price was $1.11 and its highest was $4.98 in the past 12 months.
What is Lantern Pharma, Inc.’s market cap?
Lantern Pharma, Inc.’s market cap is $36.49M.
When is Lantern Pharma, Inc.’s upcoming earnings report date?
Lantern Pharma, Inc.’s upcoming earnings report date is Aug 14, 2026 which is in 3 days.
How were Lantern Pharma, Inc.’s earnings last quarter?
Lantern Pharma, Inc. released its earnings results on May 15, 2026. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.36 by $0.06.
Is Lantern Pharma, Inc. overvalued?
According to Wall Street analysts Lantern Pharma, Inc.’s price is currently Undervalued.
Does Lantern Pharma, Inc. pay dividends?
Lantern Pharma, Inc. does not currently pay dividends.
What is Lantern Pharma, Inc.’s EPS estimate?
Lantern Pharma, Inc.’s EPS estimate is -0.38.
How many shares outstanding does Lantern Pharma, Inc. have?
Lantern Pharma, Inc. has 12,758,872 shares outstanding.
What happened to Lantern Pharma, Inc.’s price movement after its last earnings report?
Lantern Pharma, Inc. reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.36. Following the earnings report the stock price went down -4.459%.
Which hedge fund is a major shareholder of Lantern Pharma, Inc.?
Currently, no hedge funds are holding shares in LTRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lantern Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.00 (809.09% Upside)
$25.00 (809.09% Upside)
Hedge Fund Trend
Decreased
By 10.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $200.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 7.2%
Last 30 Days ▼ 7.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-35.44%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-65.76%
Trailing 12-Months
Company Description
Lantern Pharma, Inc.
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.
LTRN Company Deck
LTRN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements in clinical trial results and regulatory progress, along with advancements in AI platform commercialization. Financial stability was noted, but there is a requirement for additional funding in the near future.View all LTRN earnings summariesLTRN Stock 12 Month Forecast
Average Price Target
$25.00
▲(809.09% Upside)
Technical Analysis
Ownership Overview
1.12% Insiders
3.30% Mutual Funds
<0.01% Other Institutional Investors
92.08% Public Companies and
Individual Investors